Research Labs

13 Faculty Members found
Molecular Pharmacology Program
The Omar Abdel-Wahab Lab
Omar Abdel-Wahab, MD
Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.
Human Oncology & Pathogenesis Program
Chrysothemis Brown, MBBS, PhD
The Brown Lab studies how the tissue environment shapes immune cell fate and function during early life immune development, inflammation, and cancer.
Human Oncology & Pathogenesis Program
Human Oncology & Pathogenesis Program
Chi Lab
Ping Chi, MD, PhD
Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.
Chemical Biology Program
The Yael David Lab
Yael David, PhD
Yael David’s lab develops and applies methods in chemical biology toward studying epigenetic regulation and its correlation with disease states.
Cell Biology Program
The Lydia Finley Lab
Lydia Finley, PhD
Lydia Finley studies the mechanisms that link metabolic pathways to cell fate decisions.
Molecular Pharmacology Program
The Karuna Ganesh Lab
Karuna Ganesh, MD, PhD
Physician-scientist Karuna Ganesh studies stem cell plasticity in metastasis, therapy resistance and tissue regeneration.
Human Oncology & Pathogenesis Program
Andrew Intlekofer Lab Group
Andrew M. Intlekofer, MD, PhD
Physician-scientist Andrew Intlekofer investigates why cancer cells depend on specific pathways of nutrient metabolism.
Human Oncology & Pathogenesis Program
The Levine Lab
Ross L. Levine, MD
Mechanisms of genetic and epigenetic cooperativity which drive myeloid transformation; Elucidating and modeling evolution from hematopoietic stem/progenitor cells to clonal hematopoiesis and then to myeloid malignancies; Identification and credentialing novel therapeutic dependencies in myeloid malignancies
Chemical Biology Program
The Minkui Luo Lab
Minkui Luo, PhD
Chemical Biologist Minkui Luo develops cutting-edge tools, technologies and concepts to annotate functions of protein-posttranslational modifications and designs inhibitors for cancer therapies.